Virogen's Newsletter to Shareholders Delieanates Company's Expansion Into Worldwide Markets

MINNEAPOLIS, MN, Apr 20 (MARKET WIRE) --
Virogen, Inc. (PINKSHEETS: VRGN), the developer and patent holder of a
revolutionary vaccine to combat the deadly Newcastle disease that kills
chickens worldwide, is making public the following letter that CEO Paul
Hogan has written to the company's shareholders.

Dear Shareholders:

First I would like to extend my thanks to all those who are participating
in the support and success of the company. For all of you, as well as
those new to the company, I would like to offer the following update:

Virogen received the manufacturing and export license approval under
European Union regulatory standards at the end of July 2008. Once the
license was granted, the company aggressively began pursuing registrations
and contracts with distributors worldwide. To date, the company has signed
contracts with two major distributors in the Middle East and in Asia, and
these existing contracts are expected to be operational by July 1, 2009.

Virogen presently has $400,000 in purchase orders from these distributors
and is in the final stages of obtaining registrations in the countries
where these distributors are doing business. This process normally takes
two years, but the company has been placed on the fast track due to the
government's recognition of the urgent need and producer support for
Virogen's Innovo Newcastle Vaccine.

At this time contracts are being reviewed by several other distributors
and registrations are being pursued in Thailand, Indonesia, India, Brazil,
Russia, and China to name just a few of the markets being cultivated
simultaneously. By the second quarter of 2010, it is anticipated that the
aforementioned markets and many others will be utilizing Virogen's
vaccine.

Finally the company is implementing an aggressive R&D program to develop
new products it can introduce to the marketplace in 2010. Beginning in the
second half of 2008 and continuing through the first quarter of 2009,
Virogen has successfully executed a transition from a purely R&D company
to a commercial enterprise. The company looks forward to continued
success as it pursues this strategy and successfully executes its
business model
worldwide.

Respectfully,
Paul Hogan
Chief Executive Officer
Virogen Inc.

Investors and potential investors are invited to call Paul Hogan, CEO
Virogen, Inc. at (415) 367-4058 to request a copy of the company's
complete business plan.

Forward-Looking Statements:

This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
Virogen, Inc. and members of its management as well as the assumptions on
which such statements are based. Prospective investors are cautioned that
any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results
may differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or revise
forward-looking statements to reflect changed assumptions, the occurrence
of unanticipated events or changes to future operating results.

Paul Hogan
CEO
Virogen, Inc.
(415) 367-4058

Copyright 2009, Market Wire, All rights reserved.

-0-